Cemiplimab: Non-Surgical Option for Early CSCC | Skin Cancer Treatment

A recent approach to treating early-stage cutaneous squamous cell carcinoma (CSCC) – injecting the immunotherapy drug cemiplimab directly into the tumor – is showing encouraging results as a potential alternative to surgical removal. Presented at the Winter Clinical Miami 2026 conference, the Phase 3 CLEAR CSCC trial design suggests this intralesional cemiplimab could offer a less invasive option for appropriate patients. Cutaneous squamous cell carcinoma is a common form of skin cancer, and finding effective, non-surgical treatments is an ongoing area of research.

Understanding Cutaneous Squamous Cell Carcinoma

Cutaneous squamous cell carcinoma (CSCC) arises from the squamous cells, which make up the outer layer of the skin. It typically develops on areas frequently exposed to the sun, such as the face, ears, and hands. While often sluggish-growing, CSCC can become aggressive and spread to other parts of the body if left untreated. Current standard treatment usually involves surgical excision – physically cutting out the cancerous tissue – or, less commonly, radiation therapy. The appeal of a non-surgical approach lies in avoiding the potential for scarring, functional limitations, and the need for reconstructive surgery, particularly for tumors in cosmetically sensitive areas.

The CLEAR CSCC Trial: Design and Focus

The CLEAR CSCC trial, as reported by Dermatology Times, is a Phase 3 randomized controlled trial. Which means it’s a large-scale study designed to compare the effectiveness of intralesional cemiplimab to the current standard of care, surgical excision. The trial’s design focuses on early-stage CSCC, specifically those tumors considered low-risk for spreading. Details regarding the exact number of participants and specific inclusion/exclusion criteria haven’t been fully released yet, but the trial is actively recruiting and is expected to provide valuable data on the efficacy and safety of this new treatment approach.

Cemiplimab and Immunotherapy: How it Works

Cemiplimab is a type of immunotherapy drug called a PD-1 inhibitor. To understand how it works, it’s helpful to know a bit about the body’s immune system. Our immune system is designed to recognize and attack foreign invaders, like bacteria and viruses. Cancer cells, however, can sometimes evade the immune system by exploiting checkpoints – essentially “off switches” that prevent the immune system from attacking them. PD-1 is one such checkpoint. Cemiplimab blocks the PD-1 pathway, effectively releasing the brakes on the immune system and allowing it to recognize and destroy cancer cells.

Intralesional injection means the drug is administered directly into the tumor itself. This localized approach aims to maximize the immune response within the tumor while potentially minimizing systemic side effects – those affecting the whole body. Targeted Oncology highlights the ongoing efforts to optimize and personalize treatment strategies with cemiplimab, suggesting a move towards tailoring immunotherapy to individual patient characteristics.

What the Data Suggests (and What We Don’t Yet Know)

While the full results of the CLEAR CSCC trial are still pending, early data presented at the Winter Clinical Miami conference are promising. The trial design itself is a significant step forward, offering a rigorous framework for evaluating the effectiveness of intralesional cemiplimab. However, it’s crucial to remember that this is an ongoing study, and definitive conclusions cannot be drawn until the trial is completed and the data are fully analyzed.

Key questions remain: How does the long-term durability of response compare between intralesional cemiplimab and surgical excision? What is the rate of local recurrence with each approach? And what are the potential long-term side effects of intralesional cemiplimab? The trial will also need to assess the cost-effectiveness of this new treatment option.

Implications for Patients and the Future of CSCC Treatment

If the CLEAR CSCC trial demonstrates that intralesional cemiplimab is a safe and effective alternative to surgery, it could significantly impact the treatment landscape for early-stage CSCC. It could offer patients a less invasive option, potentially reducing scarring and preserving cosmetic outcomes. It may also be particularly beneficial for patients who are not good candidates for surgery due to age, medical comorbidities, or the location of the tumor.

The findings from this trial, and ongoing research into immunotherapy for CSCC, are part of a broader trend towards personalized medicine – tailoring treatment to the individual characteristics of each patient and their tumor. Dermatology Times’ recap of Winter Clinical Miami 2026 underscores the dynamic nature of dermatological research and the continuous pursuit of improved treatment options.

What Comes Next: Trial Completion and Guidance Updates

The next crucial step is the completion of the CLEAR CSCC trial and the thorough analysis of its results. Once the data are available, they will be submitted to regulatory agencies, such as the Food and Drug Administration (FDA) in the United States, for review. If the FDA approves intralesional cemiplimab for the treatment of early-stage CSCC, it will likely be incorporated into clinical practice guidelines issued by organizations like the National Comprehensive Cancer Network (NCCN). These guidelines provide recommendations to healthcare professionals on the best ways to diagnose and treat cancer. Ongoing surveillance will also be significant to monitor the long-term safety and effectiveness of this new treatment approach.